Clinical trials: Chronic Obstructive Pulmonary Diseases
Pulmonary Disease, Chronic Obstructive
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431274
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 239 sites in United States, Argentina and 23 more
- Volunteers
- 2,624 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00567996
- Testing
- Indacaterol 150 μg, Salmeterol 50 μg
- Where
- 128 sites in Canada, Colombia and 13 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)
The objective of this study is to compare the long-term (six month) bronchodilator efficacy and safety of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo inpatients with COPD.
- Trial name
- NCT02173691
- Testing
- Tiotropium inhalation powder capsules, Salmeterol inhalation aerosol
- Volunteers
- 584 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT00263874
- Testing
- UK-500,001
- Where
- 28 sites in Argentina, Australia and 8 more
- Volunteers
- 324 people
- Sponsor
- Pfizer
COPD
RUSSE / Russian Spiriva® Safety & Efficacy Study
At the moment, there is hardly any structured safety and efficacy data collection on Tiotropium in Russia. Therefore, the objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety…
- Trial name
- NCT00613574
- Testing
- tiotropium-bromide
- Where
- 33 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Boehringer Ingelheim
COPD, Comorbidities and Coexisting Conditions
Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease
This is a 12 month study of up to 500 people with COPD to determine if the NuvoAir clinical service leads to lower rates of severe COPD exacerbations, hospitalizations, emergency room visits, and total cost of care compared to a…
- Trial name
- PROMISE (NCT05955482)
- Testing
- NuvoAir Clinical Service
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NuvoAir Medical PC
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
- Trial name
- COPD (NCT02459080)
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 619 people
- Sponsor
- Mylan Inc.
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
HomeVent ( Connect) Registry: EU COPD Home NIV Registry
The prevalence of chronic respiratory disease, including chronic obstructive pulmonary disease (COPD), is increasing in industrialized countries.
- Trial name
- HOmeVent (NCT02811588)
- Testing
- Non-invasive ventilation
- Where
- 4 sites in Germany
- Volunteers
- 169 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD
Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen saturation (SaO2) and to characterise…
- Trial name
- NCT02182856
- Testing
- Ipratropium bromide 500 µg/salbutamol sulphate 3 mg, Ipratropium 500 µg, Salbutamol sulphate 3 mg
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD
Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017
- Trial name
- NCT02315131
- Testing
- TV46017
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Bronchitis
RejuvenAir® System Trial for COPD With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in…
- Trial name
- SPRAY-CB (NCT03893370)
- Testing
- RejuvenAir System
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 210 people
- Sponsor
- CSA Medical, Inc.
Pulmonary Disease, Chronic Obstructive
Special Survey Long-term Treatment With Tiotropium on COPD
Since Spiriva Inhalation Capsules 18mcg (hereinafter this product) are indicated for treatment of patients with chronic obstructive pulmonary disease (i.e.
- Trial name
- NCT00638183
- Where
- 89 sites in Japan
- Volunteers
- 385 people
- Sponsor
- Boehringer Ingelheim
Chronic Bronchitis
Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis.
- Trial name
- NCT03107494
- Testing
- Gala Airway Treatment System
- Where
- 2 sites in Austria, Chile
- Volunteers
- 18 people
- Sponsor
- Gala Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
CareCOPD - COPD Home Monitoring Study
This is a pilot study to demonstrate early validation of objective home-monitoring of Chronic obstructive pulmonary disease (COPD) patients by combining accurate and relevant patient data of medication and lung function (lung…
- Trial name
- NCT04918095
- Testing
- CareCOPD Platform
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cognita Labs LLC
Pulmonary Disease, Chronic Obstructive
RELOVAIR® Lung Deflation Study
The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that the treatment of lung deflation with FF/VI Inhalation Powder 100/25 mcg administered once…
- Trial name
- NCT01691885
- Testing
- Fluticasone Furoate, Vilanterol
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
- Trial name
- NCT03311373
- Testing
- Regimen A, Regimen B, Regimen C
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Breathlessness, COPD
Sentinel - Triaging Acute Breathlessness Using Multi-Modal Biomarkers
The Sentinel-001 study aims to identify a combination of biomarkers suitable for triage of breathlessness.
- Conditions
- Breathlessness, COPD, Asthma, Asthma Chronic
- Trial name
- NCT05304494
- Testing
- Biomarker tests for participant profiling
- Sponsor
- Sanome
COPD (Chronic Obstructive Pulmonary Disease)
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function…
- Trial name
- NCT07828353
- Testing
- REGEND001
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Regend Therapeutics
Emphysema
Exhale (R) Stent for Emphysema
Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation.
- Trial name
- NCT00207337
- Testing
- Exhale Drug-Eluting Stent
- Where
- 6 sites in Australia, Brazil and 1 more
- Volunteers
- 60 people
- Sponsor
- Broncus Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.